Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Invitrogen™ PAGE3 Polyclonal Antibody
Rabbit Polyclonal Antibody
Supplier: Invitrogen™ PA5104046
Description
Antibody detects endogenous levels of total PAGE3.
PAGE-3 (prostate-associated gene 3 protein), also known as GAGED1 (putative G antigen family Dmember 1), is a 113 amino acid protein that belongsto the GAGE family. The gene that encodes PAGE-3 consists of approximately 6,432 bases andmapsto human chromosome Xp11.21. Chromosome X consists of about 153million base pairs and nearly 1,000 genes. The combination of a X and Y chromosome lead to normal male development while two copies of X lead to normal female development. There are a number ofconditionsrelated to an unusual number and combination ofsexchromosomes being inherited, including Turner's syndrome, Klinefelter'ssyndrome and Triple X syndrome. Color blindness, hemophilia, and Duchennemuscular dystrophy arewellknown X chromosome-linked conditionswhich affectmalesmore frequently as males carry a single X chromosome.
Specifications
PAGE3 | |
Polyclonal | |
Unconjugated | |
PAGE3 | |
CT16.6; G antigen family D member 1; G antigen, family D, 1; GAGED1; P antigen family member 3; P antigen family, member 3 (prostate associated); PAGE family member 3; PAGE3; PAGE-3; Prostate-associated gene 3 protein | |
Rabbit | |
Affinity Chromatography | |
RUO | |
139793 | |
-20°C | |
Liquid |
Immunohistochemistry (Paraffin), Western Blot | |
1 mg/mL | |
PBS with 50% glycerol and 0.02% sodium azide; pH 7.4 | |
Q5JUK9 | |
PAGE3 | |
A synthesized peptide derived from human PAGE3(Accession Q5JUK9), corresponding to amino acid residues G25-L75. | |
100 μL | |
Primary | |
Human, Mouse | |
Antibody | |
IgG |
Safety and Handling
WARNING: Cancer - www.P65Warnings.ca.gov
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction